These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1746534)

  • 41. Treatment of "poor risk" acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside.
    Balaban EP; Cox JV; Schneider NR; Harth CA; Haley BB; Sheehan R; Frenkel EP
    Am J Hematol; 1988 Oct; 29(2):79-84. PubMed ID: 3189306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytosine arabinoside in acute leukemia of childhood.
    Traggis DG; Dohlwitz A; Das L; Jaffe N; Moloney WC; Hall TC
    Cancer; 1971 Oct; 28(4):815-8. PubMed ID: 5286443
    [No Abstract]   [Full Text] [Related]  

  • 43. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age?
    Bassan R; Barbui T
    Haematologica; 1995; 80(1):82-90. PubMed ID: 7758997
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside.
    Cassileth PA; Katz ME
    Cancer Treat Rep; 1977 Nov; 61(8):1441-5. PubMed ID: 922749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low dose cytosine arabinoside in adult acute non-lymphoid leukemia.
    Rossi Ferrini P; Ciolli S; Leoni F
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():36-7. PubMed ID: 2713558
    [No Abstract]   [Full Text] [Related]  

  • 46. High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study.
    Parikh P; Powles R; Treleaven J; Helenglass G; Gore M; Rose M; Talbot D; Milan S; Smith C; Pinkerton R
    Br J Cancer; 1990 Nov; 62(5):830-3. PubMed ID: 2245176
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
    Vogler WR; Velez-Garcia E; Omura G; Raney M
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
    [No Abstract]   [Full Text] [Related]  

  • 48. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Savani B
    Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
    Kantarjian HM; Estey EH; Plunkett W; Keating MJ; Walters RS; Iacoboni S; McCredie KB; Freireich EJ
    Am J Med; 1986 Sep; 81(3):387-94. PubMed ID: 3463209
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
    Wells RJ; Gold SH; Krill CE; Cornelius AS; Byrd RL; Ruymann FB; Feusner J; White ML; Cairo MS
    Leukemia; 1994 Oct; 8(10):1626-30. PubMed ID: 7934157
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
    Insiripong S; Thaisamakr S
    J Med Assoc Thai; 1996 Sep; 79(9):568-71. PubMed ID: 8996985
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia.
    Saşmaz I; Tanyeli A; Bayram I; Antmen B; Yilmaz L; Küçükosmanoğlu O; Kilinç Y
    Turk J Pediatr; 2004; 46(1):32-7. PubMed ID: 15074372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia.
    Crowther D; Bateman CJ; Vartan CP; Whitehouse JM; Malpas JS; Fairley GH; Scott RB
    Br Med J; 1970 Nov; 4(5734):513-7. PubMed ID: 4921703
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Value of high-dose cytosine-arabinoside in the treatment of resistant acute leukemia].
    Witz F; Olive D; Lederlin P; Bordigoni P; Troussard X; Grosbois B; Schaison G; Cornu G
    Presse Med; 1987 Feb; 16(4):159-62. PubMed ID: 2950446
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of refractory leukemia with high-dose cytosine arabinoside.
    Klener P; Háber J
    Neoplasma; 1985; 32(1):113-7. PubMed ID: 3856754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.
    Jin J; Jiang DZ; Mai WY; Meng HT; Qian WB; Tong HY; Huang J; Mao LP; Tong Y; Wang L; Chen ZM; Xu WL
    Leukemia; 2006 Aug; 20(8):1361-7. PubMed ID: 16791270
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Ochs J; Rivera GK; Pollock BH; Buchanan G; Crist W; Freeman AI
    Cancer; 1990 Oct; 66(8):1671-7. PubMed ID: 2208021
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of induction chemotherapy dose and dose intensity on the duration of remission in acute myeloid leukemia. Australian Leukemia Study Group.
    Bishop JF; Matthews JP; Young G; Szer J; Joshua DE; Dodds A; Laidlaw CR; Cobcroft R; Herrman R; Ma D
    Leuk Lymphoma; 1994 Sep; 15(1-2):79-84. PubMed ID: 7858505
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [High doses of cytosine arabinoside in the treatment of patients with acute relapsing or refractory leukemia].
    Lobato-Mendizábal E; Ruiz-Argüelles GJ; Marín-López A
    Rev Invest Clin; 1989; 41(2):139-45. PubMed ID: 2675236
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.
    Vogler WR; McCarley DL; Stagg M; Bartolucci AA; Moore J; Martelo O; Omura GA
    Leukemia; 1994 Nov; 8(11):1847-53. PubMed ID: 7967730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.